Omega-3 Fatty Acids and Vitamin D: study protocols
37 study groups took Omega-3 Fatty Acids together with Vitamin D. These are the doses the studies gave. They are not a recommendation.
Dose per serving from research: Omega-3 Fatty Acids
36 study groups in 34 studies say how much Omega-3 Fatty Acids participants took a day.
These are the doses the studies gave. They are not a recommendation.
Most common: 500 mg to 1 g, 56% of 36 study groups.
| Daily dose | Study groups |
|---|---|
| 500 mg or less | 2 |
| 500 mg to 1 g | 20 |
| 1 g to 2.5 g | 12 |
| 2.5 g to 5 g | 1 |
| over 5 g | 1 |
Dose per serving from research: Vitamin D
23 study groups in 22 studies say how much Vitamin D participants took a day.
These are the doses the studies gave. They are not a recommendation.
Most common: 1,000 IU to 2,500 IU, 61% of 23 study groups.
| Daily dose | Study groups |
|---|---|
| 500 IU or less | 1 |
| 500 IU to 1,000 IU | 2 |
| 1,000 IU to 2,500 IU | 14 |
| 2,500 IU to 5,000 IU | 1 |
| 5,000 IU to 10,000 IU | 4 |
| over 10,000 IU | 1 |
Commonly used together
12 of 37 study groups took Omega-3 Fatty Acids and Vitamin D with something else. Shown: what 3 or more different studies gave.
What was given together, not what works together.
| Taken with | Study groups |
|---|---|
| Fish Oil | 4 |
| Vitamin E | 3 |
37 study groups
| Study | ||||
|---|---|---|---|---|
| Safety and Tolerability of Targeted Medical Nutrition for Cachexia in Non-Small-Cell Lung Cancer: A Randomized, Double-Blind, Controlled Pilot Trial 2020 · juice-based TMN · Patients with non-small-cell lung cancer receiving first-line chemotherapy, with weight loss or low BMI | 2 g | 20 mcg | 12 weeks | 26 |
| Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer 2019 · n-3 fatty acids plus vitamin D group · Men aged 50 years or older and women aged 55 years or older, without selection for cardiovascular risk factors, in a primary-prevention trial | 840 mg | 2,000 IU | 1936 days | — |
| Effect of Vitamin D3 Supplements on Development of Advanced Cancer: A Secondary Analysis of the VITAL Randomized Clinical Trial 2020 · Vitamin D3 and marine omega-3 fatty acids active · Men aged 50 years or older and women aged 55 years or older without cancer or cardiovascular disease at study entry | 1 g | 2,000 IU | 1937 days | — |
| Effects of vitamin D, omega-3 fatty acids, and a simple home strength exercise program on fall prevention: the DO-HEALTH randomized clinical trial 2022 · Vitamin D plus marine omega-3 supplementation (exercise assignment varied) · Community-dwelling adults aged 70 years and older, generally healthy and active, without major health events in the prior 5 years | 1 g | 2,000 IU | 3 years | — |
| Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease: A Novel Analysis of the VITAL Trial Using Win Ratio and Hierarchical Composite Outcomes 2023 · combination supplementation group · Men aged 50 years or older and women aged 55 years or older, free of known cardiovascular disease or cancer, from the general US population | 1 g | 2,000 IU | 1935 days | — |
| Vitamin D and Marine n-3 Fatty Acids for Autoimmune Disease Prevention: Outcomes Two Years After Completion of a Double-Blind, Placebo-Controlled Trial 2024 · Vitamin D and n-3 fatty acids · Men aged 50 years or older and women aged 55 years or older, recruited from the United States; prevention population without the trial's excluded serious illnesses | 1 g | 2,000 IU | 1936 days | — |
| Vitamin D supplementation vs. placebo and incident type 2 diabetes in an ancillary study of the randomized Vitamin D and Omega-3 Trial 2025 · Vitamin D plus marine omega-3 · Men aged 50 years or older and women aged 55 years or older, without type 2 diabetes at baseline; older US adults | 840 mg | 2,000 IU | 1935 days | — |
| Targeted medical nutrition for cachexia in chronic obstructive pulmonary disease: a randomized, controlled trial 2018 · TMN · Adults aged 50 years or older with moderate-to-severe COPD and pre-cachexia or cachexia | 4 g | 20 mcg | 12 weeks | 22 |
| Effect of omega-3 and vitamin D co-supplementation on psychological distress in reproductive-aged women with pre-diabetes and hypovitaminosis D: A randomized controlled trial 2021 · Group 4 Vitamin D + Omega-3 group · Women aged 15–50 with pre-diabetes and hypovitaminosis D | 2 g | — | 8 weeks | 42 |
| The Effects of Omega-3 Fatty Acids and Vitamin D Supplementation on the Nutritional Status of Women with Breast Cancer in Palestine: An Open-Label Randomized Controlled Trial 2024 · group 3: both omega-3 and vitamin D supplementation (ω3+VitD) · Women aged 28–64 with newly diagnosed stage II or III breast cancer, before first chemotherapy treatment | 600 mg | 7,143 IU | 9 weeks | 24 |
| Inflammation (IL-1β) Modifies the Effect of Vitamin D and Omega-3 Long Chain Polyunsaturated Fatty Acids on Core Symptoms of Autism Spectrum Disorder-An Exploratory Pilot Study(‡) 2020 · vitamin D and omega-3 LCPUFA (VIDOM) · Children aged 2.5–8 years with autism spectrum disorder | 722 mg | 2,000 IU | 1 year | 15 |
| Effect of vitamin D and omega-3 on nocturnal enuresis of 7-15-year-old children 2018 · Group C · Children aged 7–15 with nocturnal enuresis | 1 g | 1,000 IU | 60 days | — |
| Low-Dose Omega-3 Fatty Acid and Vitamin D for Anthropometric, Biochemical Blood Indices and Respiratory Function. Does it work? 2020 · experimental group · Office workers aged 40–60 years; sex and health condition not stated | 330 mg | 5 mcg | 16 weeks | — |
| The effects of Omega-3 fatty acids and vitamin D supplementation on the quality of life and blood inflammation markers in newly diagnosed breast cancer women: An open-labelled randomised controlled trial 2025 · ω3+VitD group · Women newly diagnosed with breast cancer receiving chemotherapy; age range not reported | 600 mg | 7,143 IU | 9 weeks | — |
| Effects of vitamin D3, omega-3 fatty acids and a simple home exercise program on change in physical activity among generally healthy and active older adults: The 3-year DO-HEALTH trial 2025 · Vitamin D3 and omega-3s, without SHEP · Generally healthy, community-dwelling adults aged 70 years or older; men and women | 1 g | 2,000 IU | 3 years | — |
| Effects of vitamin D3, omega-3 fatty acids and a simple home exercise program on change in physical activity among generally healthy and active older adults: The 3-year DO-HEALTH trial 2025 · Vitamin D3 and omega-3s with SHEP · Generally healthy, community-dwelling adults aged 70 years or older; men and women | 1 g | 2,000 IU | 3 years | — |
| Reduction in behavior problems with omega-3 supplementation in children aged 8-16 years: a randomized, double-blind, placebo-controlled, stratified, parallel-group trial 2015 · omega-3 group · Children aged 8–16 years living in the community | 2 g | 0.85 mcg | 26 weeks | 100 |
| Nutritional supplementation to reduce child aggression: a randomized, stratified, single-blind, factorial trial 2016 · Nutrition + CBT · Children aged 11–12 years at high risk for aggression or antisocial behavior, including full or borderline conduct disorder or oppositional defiant disorder criteria, or elevated proactive or reactive aggression scores | 1 g | — | 90 days | 73 |
| Effects of a 6-Month Multifaceted Diet and Exercise Intervention on Cognition in Older Adults at Risk of Cognitive Decline: The PONDER Double-Blind, Placebo-Controlled Randomized Trial 2022 · Multimodal exercise program with daily supplement · Community-dwelling older adults with subjective memory impairment; mean age 70.2 years, 70% female | 1.5 g | 1,000 IU | 26 weeks | 73 |
| Nutritional supplementation to reduce child aggression: a randomized, stratified, single-blind, factorial trial 2016 · Nutrition only · Children aged 11–12 years at high risk for aggression or antisocial behavior, including full or borderline conduct disorder or oppositional defiant disorder criteria, or elevated proactive or reactive aggression scores | 1 g | — | 90 days | 72 |
| Effect of Omega-3 Polyunsaturated Fatty Acid Supplementation on Clinical Outcome of Atopic Dermatitis in Children 2024 · intervention group · Children aged 1–8 years with moderate-to-severe atopic dermatitis | 600 mg | 5 mcg | 120 days | 26 |
| The effects of omega-3 fatty acid on vitamin D activation in hemodialysis patients: a pilot study 2015 · Cholecalciferol with omega-3 FA group · Hemodialysis patients with baseline 25(OH)D levels below 30 ng/mL; mean age 62.1 years; 33.3% men | 2.4 g | 7,143 IU | 12 weeks | 8 |
| Combined Effect of Omega-3 Fatty Acid and Vitamin D 3 on Oxidized LDL-C and Non-HDL-C Levels in People With Vitamin D Deficiency: A Randomized Controlled Trial 2023 · D+ group · Jordanian participants with vitamin D deficiency and no other medical conditions; age and sex not specified | 300 mg | 7,143 IU | 8 weeks | 47 |
| The effects of fish oil plus vitamin D(3) intervention on non-alcoholic fatty liver disease: a randomized controlled trial 2022 · FO + D group · Adults aged 56.0 ± 15.9 years with non-alcoholic fatty liver disease | 2.34 g | 1,680 IU | 90 days | 37 |
| The effects of vitamin D and omega-3 fatty acid co-supplementation on glycemic control and lipid concentrations in patients with gestational diabetes 2017 · vitamin D + omega-3 fatty acids · Patients with gestational diabetes; age and sex not otherwise specified | 2 g | — | 6 weeks | 35 |
| The influences of vitamin D and omega-3 co-supplementation on clinical, metabolic and genetic parameters in women with polycystic ovary syndrome 2018 · Vitamin D and omega-3 co-supplementation · Women aged 18–40 years with polycystic ovary syndrome (PCOS) | 2 g | — | 12 weeks | 30 |
| Long-term vitamin D and high-dose n-3 fatty acids' supplementation improve markers of cardiometabolic risk in type 2 diabetic patients with CHD 2019 · Vitamin D and n-3 fatty acids co-supplementation · Vitamin D-deficient patients with type 2 diabetes and coronary heart disease; age and sex not reported | 2 g | — | 26 weeks | 30 |
| Impact of Omega-3 and Vitamin D Supplementation on Bone Turnover Markers in Children with Leukemia: Follow-Up During and After Supplementation 2025 · ω-3VDCa group · Children aged 5–17 years with acute lymphoblastic leukemia in the maintenance phase | 100 mg/kg | 4,000 IU | 6 weeks | 19 |
| The Effect of Omega-3 Fatty Acid Supplementation on Serum Adipocytokines, Lipid Profile and Biochemical Markers of Inflammation in Recreational Runners 2021 · ω-3 PUFA group · Healthy physically active male recreational marathon runners, with no stated disease; age range not reported | 2.45 g | 30 mcg | 3 weeks | 12 |
| Prenatal dietary supplements influence the infant airway microbiota in a randomized factorial clinical trial 2020 · n-3 LCPUFA plus vitamin D · Pregnant women enrolled at pregnancy week 24; age range and health condition not specified | 2.4 g | 2,400 IU | 17 weeks | — |
| The effect of combined supplementation with vitamin D and omega-3 fatty acids on blood glucose and blood lipid levels in patients with gestational diabetes 2021 · test group · Women aged 18–40 with gestational diabetes | 16 g | 80,000 IU | 6 weeks | — |
| Effects of Vitamin D(3) and Marine Omega-3 Fatty Acids Supplementation on Biomarkers of Systemic Inflammation: 4-Year Findings from the VITAL Randomized Trial 2022 · Vitamin D3 and marine n-3 fatty acids active group · Men aged 50 years or older and women aged 55 years or older, without a history of cancer (except non-melanoma skin cancer), myocardial infarction, stroke, transient ischemic attack, or coronary revascularization | 1 g | 2,000 IU | 1935 days | — |
| Vitamin D(3) and marine ω-3 fatty acids supplementation and leukocyte telomere length: 4-year findings from the VITamin D and OmegA-3 TriaL (VITAL) randomized controlled trial 2025 · Vitamin D3 plus marine n-3 fatty acids · Females aged 55 years or older and males aged 50 years or older; no specific condition stated | 1 g | 2,000 IU | 5 years | — |
| Plasma Instead of Serum Avoids Critical Confounding of Clinical Metabolomics Studies by Platelets 2024 · Omega-3 treatment cohort · Healthy adults; age and sex not specified for this cohort | 1.74 g | 10 mcg | 7 days | 6 |
| Potential Modulation of Inflammation by Probiotic and Omega-3 Supplementation in Elderly with Chronic Low-Grade Inflammation-A Randomized, Placebo-Controlled Trial 2022 · Active treatment group · Adults aged 65–80 with low-grade inflammation (hs-CRP 1.5–6 mg/L) and BMI 18.5–27 kg/m² | 640 mg | 200 IU | 8 weeks | — |
| Multimicronutrient and omega-3 fatty acid supplementation reduces low-grade inflammation in older participants: An exploratory study 2025 · multimicronutrient and n-3 PUFA supplementation · Healthy, physically active older adults; mean age 75.6 ± 3.9 years; sex not specified | 1 g | 50 mcg | 12 weeks | — |
| Effects of Vitamin D, Omega-3 Fatty Acids and a Home Exercise Program on Prevention of Pre-Frailty in Older Adults: The DO-HEALTH Randomized Clinical Trial 2023 · Vitamin D3 plus marine omega-3s · Generally healthy, robust, community-dwelling adults aged 70 years or older | 1 g | 2,000 IU | 3 years | — |